@article{12729dbf75f14a7ba551b37b25f76f23,
title = "Editorial Comment: Vital Iodine Tumor Burden on Dual-Energy CT Outperforms Conventional CT Metrics of Response in Patients With GIST Undergoing Tyrosine Kinase Inhibitor Therapy",
author = "Ludwig, {Daniel R.}",
note = "Funding Information: This study compared DECT vital iodine tumor burden (TB), in essence the volume of tumor that enhances with iodinated contrast material, to other CT-and PET-based metrics of response, including RECIST 1.1, modified Choi (mChoi) criteria, vascular tumor burden (VTB) criteria, and European Organization for Research and Treatment of Cancer (EORTC) PET criteria criteria, for the assessment of progression-free survival. The results show that vital iodine TB outperformed RECIST 1.1 and mChoi criteria and was comparable to EORTC PET and VTB criteria. This well-conducted study is supported by a phantom component with simulated GIST lesions to validate a threshold to discriminate vital from nonvital tissue. The article provides strong support for the use of DECT vital iodine TB for assessing treatment response in patients with GIST undergoing TKI-based therapy.",
year = "2022",
month = apr,
doi = "10.2214/AJR.21.26994",
language = "English",
volume = "218",
pages = "669",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
number = "4",
}